Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN608 in Advanced Solid Tumors
NCT07088588Phase 1Not yet recruiting
- Sponsor
- SynRx Therapeutics
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of syn608 in solid tumor, breast cancer and ovarian cancer, sponsored by SynRx Therapeutics. Primary endpoints: Maximum Tolerated Dose up to 3 years, Number of participants with Dose Limiting Toxicities and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
syn608
03
Conditions
solid tumorbreast cancerovarian cancer
Beyond the preview
Go deeper on NCT07088588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088588.